Lung Cancer

Heather A. Wakelee, MD, professor of medicine, Stanford University Medical Center, discusses the rationale to explore osimertinib (Tagrisso) in combination with concurrent chemotherapy in patient with EGFR-mutant non–small cell lung cancer.

Lowell L. Hart, MD, FACP, scientific director of Clinical Research at Florida Cancer Specialists & Research Institute, and associate professor of Internal Medicine at Wake Forest School of Medicine, discusses the impact of trilaciclib on myelosuppression in patients with previously treated extensive-stage small cell lung cancer.

Mark G. Kris, MD, discusses the RELAY trial, which was an international, double-blind, randomized phase III study examining erlotinib in combination with ramucirumab versus placebo in previously untreated patients with EGFR-mutant metastatic non-small cell lung cancer.

AbbVie has officially ended its rovalpituzumab tesirine (Rova-T) research and development program, which was exploring the antibody-drug conjugate in patients with small cell lung cancer.

Jüergen Wolf, MD, medical director, Center for Integrated Oncology, professor, Interdisciplinary Translational Oncology at University Hospital of Cologne, discusses the primary efficacy data of the phase II GEOMETRY mono-1 trial exploring the MET inhibitor capmatinib as treatment for patients with non-small cell lung cancer and exon-14 mutations.

Edward B. Garon, MD, MS, highlights the 5-year KEYNOTE-001 data and also the activity with lurbinectedin in small cell lung cancer.

Practice-changing phase III trials including KEYNOTE-189, KEYNOTE-407, REVEL, and IMpower131, among several others, are laying the groundwork for how to treat patients with non–small cell lung cancer, specifically on an individualized basis.

Suresh A. Ramalingam, MD, discusses recent updates in EGFR-mutant non–small cell lung cancer and the next steps for osimertinib and other agents in this patient population.

A new drug application will be submitted to the FDA under accelerated approval status for lurbinectedin monotherapy for the second-line treatment of patients with small cell lung cancer, according to PharmaMar, the developer of the marine-derived agent.

Using up-front, broadpanel genomic tests that include hundreds of genes can save money and, in some cases, improve outcomes compared with other diagnostic approaches, especially in lung cancer but also increasingly in breast, colorectal, skin, and other cancers.

Combining the PARP inhibitor olaparib (Lynparza) with temozolomide (Temodar) led to an overall response rate of 41.7% in patients with relapsed small cell lung cancer.

The FDA has granted an accelerated approval to entrectinib for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor a NTRK fusion, and has also approved the agent for the treatment of adults with ROS1-positive, metastatic non–small cell lung cancer.

Badi El-Osta, MD, discusses the targeted agents that are showing the most promise for patients with non–small cell lung cancer who have rare alterations and variants.

Conor E. Steuer, MD, discusses emerging agents in the treatment of patients with ALK- or ROS1-positive non–small cell lung cancer and the sequencing challenges that have resulted in the space.

Frontline osimertinib significantly improved overall survival compared with erlotinib or gefitinib in patients with EGFR-positive local advanced or metastatic non–small cell lung cancer, according to results from the phase III FLAURA trial.

Taofeek Owonikoko, MD, PhD, MSCR, discusses the results of the NLST and NELSON trials and the next steps that need to be addressed with lung cancer screening.

Anna F. Farago, MD, PhD, discusses the second-line data with lurbinectedin and its potential impact on the small cell lung cancer field.

Jonathan Riess, MD, MS, discusses ongoing research with PARP inhibitors in lung cancer and potential biomarkers for this class of agents.

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

Sarah B. Goldberg, MD, MPH, discusses the combination of immunotherapy and targeted therapy for the treatment of patients with oncogene-driven lung cancer.

Treatment with afatinib (Gilotrif) followed by osimertinib (Tagrisso) led to a median overall survival of 41.3 months and a 2-year OS rate of 80% in patients with EGFR T790M-positive non–small cell lung cancer in a real-world setting.

As the immunotherapy research field grows, NY-ESO-1 is emerging as a high-priority target for cancer vaccine development and adoptive T-cell therapies.

Alice T. Shaw, MD, PhD, associate professor of medicine at Harvard Medical School, director of Thoracic Oncology and Paula O’Keefe Endowed Chair in Thoracic Oncology at Massachusetts General Hospital, discusses sequencing strategies in ALK-positive non–small cell lung cancer (NSCLC).

Konstantinos Arnaoutakis, MD, discusses pivotal updates in stage III disease, immunotherapy combinations in advanced non–small cell lung cancer, and advances in EGFR- and ALK-mutated lung cancer.